280E Relief Lands: Trulieve Posts $287M Q1 Revenue and a 35% EBITDA Margin

Trulieve Cannabis Corp reported Q1 2026 revenue of $287 million on May 8 — the first earnings release filed since Acting Attorney General Todd Blanche's April 23 order moved state-licensed medical cannabis to Schedule III. The headline number was solid, up from $283 million a year prior. The number that matters, though, is buried two lines down the income statement: adjusted EBITDA of $100 million, a 35 percent margin, and operating cash flow of $42 million.

Behind those numbers is the structural change that has been delayed across two administrations and now lands all at once. Section 280E of the Internal Revenue Code — which prohibited taxpayers trafficking in Schedule I or II controlled substances from deducting ordinary business expenses — no longer applies to the medical side of Trulieve's business. For calendar-year taxpayers, the relief flows from January 1, 2026 forward. (S1, S2)

Cannabis operators have, for the better part of a decade, paid effective federal tax rates that analysts have placed in the 70-to-75 percent range. That is not a typo. 280E disallowed deductions for wages, rent, marketing, depreciation — everything ordinary about running a retail business. Operators paid federal income tax on a tax base that was, in effect, gross profit minus only cost of goods sold.

Schedule III is not on the 280E list. For Trulieve, which derives the majority of its revenue from medical operations across nine states, the relief lands immediately. The 35 percent EBITDA margin reflects, in part, that the company was operating Q1 under the assumption medical rescheduling would close in time to claim deductions for the period. That bet paid off six days before quarter-end.

For multistate operators with both medical and recreational revenue, the rescheduling bifurcates the federal tax regime inside a single legal entity. Medical revenue is 280E-clean. Recreational revenue still carries the full 280E load. Allocations between the two — particularly for shared expenses like real estate, IT, and corporate overhead — become a material accounting question, and one the IRS has not yet issued specific guidance on.

For single-state medical-only operators — particularly in Florida, Pennsylvania, and Ohio, three states without recreational programs — the picture is cleaner. They get full 280E relief on the full business. For these operators, the rescheduling represents perhaps the single largest improvement to cannabis P&L economics since the commercial inception of the industry.

The capital-markets implication is mixed. The industry's roughly $6 billion in debt coming due by end-2026 — concentrated in five MSOs that collectively owe $3.4 billion — gets a different reception in refinancing conversations now that the medical side of every borrower is federally registered and 280E-clean. Whether that translates into materially lower coupons on refinancing is being tested in real time.

Trulieve CEO Kim Rivers, in the company's Q1 release, framed the moment in patient terms — the language the medical operators have leaned on since the rescheduling debate began.

“DEA registration for our medical business marks a historic step forward for Trulieve and the patients we serve.”

— Kim Rivers, CEO, Trulieve Cannabis Corp

Equity analysts have been less euphoric. The MSO sector, currently 29 publicly traded companies with a combined market capitalization of roughly $7 billion, still trades at median EV/EBITDA multiples in the mid-single digits — well below comparable consumer-staples or specialty-retail peers. The market is pricing in 280E relief but not yet pricing in the broader Schedule III expansion that the June 29 DEA administrative hearing will start considering.

1. Q2 2026 earnings (August-September) — the first FULL quarter of post-rescheduling P&L. Expect medical-heavy operators to print materially better adjusted EBITDA margins. The number to watch: medical-revenue mix as a percentage of total revenue.
2. June 29, 2026 — DEA administrative hearing on broader rescheduling begins. If the hearing trajectory suggests adult-use cannabis follows medical into Schedule III, the entire sector revalues.
3. Refinancing wave through Q3-Q4 2026 — the maturity calendar on the $6 billion debt wall starts coming due in earnest. Expect coupon compression for medical-heavy operators; expect the recreational-only operators to face the same lender pricing they did pre-rescheduling.
4. IRS guidance on medical/recreational expense allocation — not yet published. Operators with split-state businesses are running on best-effort allocations. When official guidance lands, expect retroactive amendments to Q1 2026 returns.

The open question is whether the equity-market revaluation will lead or lag the operating numbers. Q1 was the proof. Q2 will be the test.